TLX (Telix Pharmaceuticals) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


TLX Telix Pharmaceuticals Ltd TLX
50 GF Score
Price $10.86
GF Value $27.71
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Telix Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

TLX vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Telix Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telix Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


TLX
50GF Score
Telix Pharmaceuticals Ltd TLX
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Telix Pharmaceuticals (TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $10.86 is trading 60.8% below its estimated GF Value™ of $27.71. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLX:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $27.71 vs. price of $10.86 (60.8% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score

Get the complete analysis for TLX

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.86
Price
$27.71
GF Value